- Home
- » Tags
- » Pioglitazone
Top View
- Insulin Glargine and Detemir Pioglitazone Exenatide Liraglutide
- Update on Insulin Management in Type 2 Diabetes
- Approach to a Safer Insulin Sensitizer
- Ryzodeg 70/30 PI
- Post-Treatment with the PPAR-Γ Agonist Pioglitazone Inhibits
- ACTOS® (Pioglitazone Hydrochloride) Tablets
- Combination Treatment with Pioglitazone and Fenofibrate
- MEDICATION GUIDE Alogliptin and Pioglitazone Tablets Read This
- Ryzodeg, INN-Insulin Degludec/Insulin Aspart
- Netoglitazone Is a PPAR-Gamma Ligand with Selective Effects on Bone and Fat ⁎ Oxana P
- Package Leaflet: Information for the Patient Pioglitazone 15 Mg Tablets Pioglitazone 30 Mg Tablets Pioglitazone 45 Mg Tablets Pi
- (Insulin Plus Oral Medication) in Type 2 Diabetes?
- Peroxisome Proliferator-Activated Receptor Gamma Agonist As a Novel Treatment for Interstitial Cystitis: a Rat Model
- Comparison of Insulin Degludec/Insulin
- Diabetes Management Medications
- Pioglitazone for the Treatment of Type 2 Diabetes in Patients Inadequately Controlled on Insulin
- Insulin Degludec/Insulin Aspart (Degludecplus) for Type 2 Diabetes
- The Multi-Facets of the Antitumor Effect of Thiazolidinediones
- ISSN: 0975-8585 May-June 2014 RJPBCS 5(3) Page No. 1297
- Ciglitazone Negatively Regulates CXCL1 Signaling Through MITF to Suppress Melanoma Growth
- The Antidiabetic Drug Lobeglitazone Protects Mice from Lipogenesis-Induced Liver Injury Via Mechanistic Target of Rapamycin Complex 1 Inhibition
- Rethinking Pioglitazone As a Cardioprotective Agent
- Adding Pioglitazone to Insulin Containing Regimens in Type 2 Diabetes: Systematic Review and Meta-Analysis
- Original Article
- Pioglitazone and Rosiglitazone
- Favorable Cardiovascular Effects of Pioglitazone: a Meta-Analysis
- Combination Therapy with Exenatide Plus Pioglitazone Versus Basal
- Pioglitazone Hydrochloride Monotherapy Improves Glycemic Control in the Treatment of Patients with Type 2 Diabetes
- Pioglitazone Hydrochloride)
- Improvement of Glycemic Control, Triglycerides, And
- Pparγ-Independent Side Effects of Thiazolidinediones on Mitochondrial Redox State in Rat Isolated Hearts
- ACTOS™ (Pioglitazone Hydrochloride) Tablets NDA No
- Soluble Co-Formulation of Insulin Degludec and Insulin Aspart: a New Approach to Insulin Treatment
- Actos, INN-Pioglitazone
- Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor Γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
- Quantitative Structural Assessment of Graded Receptor Agonism
- Pioglitazone: Lessons and Learnings 15 Years Since Launch and Beyond
- Molecular Modeling Study of Pparγ Agonists: Dehydro-Di-Isoeugenol, Macelignan, Pioglitazone, Netoglitazone, and Rosiglitazone As Antidiabetic Drugs
- Pioglitazone in the Management of Type 2 Diabetes and Beyond
- Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus
- Antihyperglycemic Agents Comparison Chart
- (PPAR)-Γ and -Α Agonists on Cochlear Protection from Oxidative Stress
- Effect of a Dual PPAR Α/Γ Agonist on Insulin Sensitivity in Patients Of
- Actos, INN-Pioglitazone Hydrochloride
- Effects of Pioglitazone on Glucose Dependent Insulinotropic Polypeptide Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients with Type 2 Diabetes
- The Role of Pioglitazone in the Treatment of Type 2 Diabetes - Update 2016
- Pioglitazone (Actos) for Type 2 Diabetes
- Saroglitazar: a New Drug to Treat Diabetic
- Diabetes in Primary Care; Getting A1C to Goal. Generics to Novel Agents
- Pioglitazone, a Ligand for Peroxisome Proliferator-Activated Receptor-Γ
- Saroglitazar
- The Journey of Thiazolidinediones As Modulators of Ppars for the Management of Diabetes: a Critical Review